Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress New non-interventional study (VITOBA TM) aims to investigate additive or ...

Topline results of a phase 3 trial support a supplemental New Drug Application for lacosamide (Vimpat, UCB) as monotherapy for patients with partial-onset seizures, the company has announced.

Motpoly XR is bioequivalent to Vimpat (lacosamide) film-coated tablets and provides a new once-daily option at equivalent doses. Motpoly XR™ (lacosamide) extended-release capsules are now available ...

Active ingredient: Lacosamide 10 mg/mL; solution for IV infusion. Indication: Adjunct in partial-onset seizures, when oral administration is not feasible. Pharmacology: Lacosamide selectively enhances ...

Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

NEW ORLEANS – The anti-epileptic agent lacosamide (Vimpat) appears to give relief to patients with refractory trigeminal neuralgia, researchers reported here. Principal investigator Jeffrey Cohen, MD, ...

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures ...

Please provide your email address to receive an email when new articles are posted on . Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes was well tolerated and ...

BRUSSELS, BELGIUM--(Marketwire - July 29, 2008) - 6 pm CEST - press release, regulated information: UCB announced today that it received a not-approvable letter from the U.S. Food and Drug ...